Congress Materials – Masterclass in Dermatology 2025

This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.

Sustained Improvements in Psoriasis Area and Severity Index and in Percent Body Surface Area of Psoriasis With JNJ-77242113 in Patients With Moderate-to-Severe Plaque Psoriasis: Treat-to-Target Analyses in the FRONTIER 1 & 2 Studies

Kim A. Papp, Laura K. Ferris, Andreas Pinter, Phoebe Rich, Ronald Bernard Vender, Andrew E. Pink, Takayuki Ota, Yaung-Kaung Shen, Shu Li, Amy M. DeLozier, Jessica Vasquez, Ya-Wen Yang, Robert Bissonnette

 

View poster

VISIBLE: Guselkumab Impact on Psoriatic Arthritis Through Week 48 in Participants With Moderate-to-Severe Psoriasis Across All Skin Tones

AB Gottlieb, A McMichael, T Bhutani, O Choi, K Rowland, T Alkousakis, J Vasquez, T Ma, SD Chakravarty, D Chan, A Nguyen, SR Desai, A Alexis, JF Merola

 

View poster